MAXCYTE, INC. — Form SCHEDULE 13D
Filed November 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Liontrust Investment Partners LLP, a UK-based investment firm, filed a Schedule 13D with the SEC on November 2, 2026, indicating acquisition of beneficial ownership in MaxCyte, Inc. The filing text does not disclose the specific share count, percentage ownership, dollar amount of the investment, or the timing/circumstances of the acquisition. Without these material details, the substance and significance of this filing cannot be determined.
Why this rating
Schedule 13D alone signals potential activist involvement or significant stake, but absent disclosed ownership %, shares, or price, cannot assess materiality versus $231M market cap.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.